Home › Compare › LOUIF vs ABBV
LOUIF yields 20000.00% · ABBV yields 3.06%● Live data
📍 LOUIF pulled ahead of the other in Year 1
Combined, LOUIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LOUIF + ABBV for your $10,000?
South Shore Holdings Limited, an investment holding company, engages in the hospitality, entertainment, and construction businesses in Hong Kong, Macau, Singapore, and Malaysia. It operates through Management Contracting, Property Development Management, Property Investment, and Hotel Operation segments. The Management Contracting segment offers building construction and civil engineering services. The Property Development Management segment develops and manages projects, as well as provides facilities and asset management services. The Property Investment segment invests in properties. The Hotel Operation segment operates hotels with ancillary facilities. The company also offers electrical, mechanical, and building services, as well as finance, interior decoration and foundation works, and management and secretarial services. In addition, it is involved in the trade and letting of plant and machinery; and trade and installation of building materials. The company was formerly known as The 13 Holdings Limited and changed its name to South Shore Holdings Limited in June 2018. South Shore Holdings Limited was founded in 1946 and is based in Quarry Bay, Hong Kong.
Full LOUIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.